The Experts below are selected from a list of 2772 Experts worldwide ranked by ideXlab platform
Kun Cheng - One of the best experts on this subject based on the ideXlab platform.
-
Co-delivery of IKBKE siRNA and cabazitaxel by hybrid Nanocomplex inhibits invasiveness and growth of triple-negative breast cancer.
Science advances, 2020Co-Authors: Zhen Zhao, Akshay Jain, Hao Liu, Pratikkumar Patel, Kun ChengAbstract:IKBKE is an oncogene in triple-negative breast cancer (TNBC), and we demonstrate that IKBKE small interfering RNA (siRNA) inhibits the proliferation, migration, and invasion of TNBC cells. Despite the recent success of siRNA therapeutics targeting to the liver, there still remains a great challenge to deliver siRNAs to solid tumors. Here, we report a hybrid Nanocomplex to co-deliver the IKBKE siRNA and cabazitaxel to TNBC to achieve an optimal antitumor effect. The Nanocomplex is modified with hyaluronic acid to target CD44 on TNBC cells. The Nanocomplex shows higher cellular uptake and better tumor penetration of the encapsulated cargos. The Nanocomplex also exhibits high tumor accumulation and antitumor activity in an orthotopic TNBC mouse model. Encapsulation of cabazitaxel in the Nanocomplex enhances the activity of the IKBKE siRNA. The hybrid Nanocomplex provides a novel and versatile platform for combination therapies using siRNAs and chemotherapy.
-
Abstract 351: A targeted Nanocomplex of the IKBKE siRNA inhibits invasiveness and growth of triple negative breast cancer cells
Experimental and Molecular Therapeutics, 2019Co-Authors: Zhen Zhao, Kun ChengAbstract:IκB kinase e (IKBKE, or known as IKKe), an important mediator in the activation of NF-κB pathway, was recently identified as an oncogene in breast cancer and overexpressed in approximately 30% of breast carcinomas. It is also highly expressed in TNBC cells, which is correlated with angiogenesis process, high metastasis in NF-κB pathway of TNBC. We found that silencing IKBKE in TNBC cells using siRNA significantly inhibits the proliferation, migration and invasion of TNBC cells by specific silenced 71% of IKBKE in vitro. In vivo study indicated that IKBKE siRNA can inhibit TNBC tumor growth after peritumoral injection at a IKBKE siRNA dose of 0.3 mg/kg. We next developed a CD44-targeting, cholesterol-peptide based Nanocomplex to co-deliver the IKBKE siRNA and cabazitaxel to TNBC cells. The Nanocomplex showed the synergistic effect of the IKBKE siRNA and cabazitaxel on inhibiting the growth of TNBC tumors in vivo. Modification of the Nanocomplex with CD44 further improved tumor uptake and anti-tumor efficacy of the Nanocomplex. Our results suggest that IKBKE siRNA is a promising anti-tumor agent for TNBC therapy, and co-delivery of IKBKE siRNA and cabazitaxel using a CD44-targeting Nanocomplex is a potential strategy for TNBC treatment. Moreover, this multifunctional delivery system provides a platform for other combination therapy including an siRNA and a chemotherapy drug. Citation Format: Zhen Zhao, Yuanke Li, Kun Cheng. A targeted Nanocomplex of the IKBKE siRNA inhibits invasiveness and growth of triple negative breast cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 351.
-
Targeted Delivery of an siRNA/PNA Hybrid Nanocomplex Reverses Carbon Tetrachloride-Induced Liver Fibrosis.
Advanced therapeutics, 2019Co-Authors: Akshay Jain, Ashutosh Barve, Zhen Zhao, John Peter Fetse, Hao Liu, Kun ChengAbstract:Liver fibrosis is a wound healing process with excessive accumulation of extracellular matrix in the liver. We recently discovered a PCBP2 siRNA that reverses fibrogenesis in activated hepatic stellate cells (HSCs), which are the key players in liver fibrogenesis. However, targeted delivery of siRNAs to HSCs still remains a challenge. Herein, we developed a new strategy to fabricate a multicomponent Nanocomplex using siRNA/PNA hybrid instead of chemically conjugated siRNA, thus increasing the scalability and feasibility of the siRNA Nanocomplex for animal studies. We modified the Nanocomplex with an insulin growth factor 2 receptor (IGF2R)-specific peptide, which specifically binds to activated HSCs. The siRNA Nanocomplex shows a controllable size and high serum stability. The Nanocomplex also demonstrates high cellular uptake in activated HSCs in vitro and in vivo. Anti-fibrotic activity of the siRNA Nanocomplex was evaluated in rats with carbon tetrachloride-induced liver fibrosis. Treatment with the PCBP2 siRNA Nanocomplex significantly inhibits the mRNA expressions of PCBP2 and type I collagen in fibrotic liver. Histology study revealed that the siRNA Nanocomplex efficiently reduces the protein level of type I collagen and reverses liver fibrosis. Our data suggest that the Nanocomplex efficiently delivers the siRNA to fibrotic liver and produces a potent anti-fibrotic effect.
-
Development of a Biocompatible Copolymer Nanocomplex to Deliver VEGF siRNA for Triple Negative Breast Cancer.
Theranostics, 2019Co-Authors: Zhen Zhao, Akshay Jain, Ashutosh Barve, Hao Liu, Ravi S. Shukla, Kun ChengAbstract:Triple negative breast cancer (TNBC) is the most difficult breast cancer subtype to treat. TNBC patients have significantly higher expression of vascular endothelial growth factor (VEGF) in tumors compared to non-TNBC patients. VEGF not only exerts its pro-angiogenic effects on endothelial cells but also acts as a survival and autocrine growth factor for VEGF receptor (VEGFR) expressing cancer cells. Silencing the expression of VEGF is therefore a potential therapy for TNBC. Methods: A novel biocompatible linear copolymer poly[bis(e-Lys-PEI)Glut-PEG] (PLEGP) was developed to deliver VEGF siRNA for TNBC therapy. The copolymer is composed of lysine and glutaric acid, a natural metabolite of amino acids in the body. Low-molecular weight polyethyleneimine (PEI) was grafted to the copolymer to efficiently condense siRNA into Nanocomplex without inducing cytotoxicity. Various in vitro studies were performed to evaluate the stability, cellular uptake, tumor penetration, and biological activities of the VEGF siRNA Nanocomplex. The anti-tumor activities of the Nanocomplex was also evaluated in an orthotopic TNBC mouse model. Results: PEIs with different molecular weights were evaluated, and the copolymer PLEGP1800 was able to easily form a stable Nanocomplex with siRNAs and protect them from serum degradation. The siRNA/PLEGP1800 Nanocomplex exhibited negligible cytotoxicity but showed high cellular uptake, high transfection efficiency, and high tumor penetration. In vitro activity studies showed that the siRNA Nanocomplex significantly inhibited migration and invasion of TNBC cells. Moreover, the VEGF siRNA Nanocomplex efficiently inhibited tumor growth in an orthotopic TNBC mouse model and down-regulated VEGF expression in the tumor. Conclusion: PLEGP1800 is a safe and efficient copolymer to deliver siRNAs for TNBC therapy. It could potentially be applied to other cancers by changing the cargo and incorporating tumor-specific ligands.
-
Development of a peptide-modified siRNA Nanocomplex for hepatic stellate cells.
Nanomedicine : nanotechnology biology and medicine, 2017Co-Authors: Zhen Zhao, Akshay Jain, Hao Liu, Wei Jin, Zhijin Chen, Kun ChengAbstract:Insulin-like growth factor 2 receptor (IGF2R) is overexpressed in activated hepatic stellate cells (HSCs) and therefore can be utilized for HSC-specific drug delivery. We recently discovered an IGF2R-specific peptide using a novel biopanning. Here, we adopted biotin-conjugated IGF2R-specific peptide, cholesterol, and vitamin A as the targeting ligands for the neutravidin-based siRNA Nanocomplex to deliver PCBP2 siRNA, a potentially antifibrotic agent, to HSCs. Compared to vitamin A and cholesterol, the IGF2R-specific peptide exhibited the highest targeting effect to human LX-2 HSC, rat HSC-T6 cell line, and activated primary rat HSCs. Accordingly, the IGF2R-specific peptide coupled Nanocomplex demonstrated higher silencing activity of PCBP2 and better inhibition on the migration of activated HSCs. Compared to free siRNA and the Nanocomplexes coupled with vitamin A and cholesterol, the IGF2R-specific peptide coupled Nanocomplex showed the highest uptake in the liver and lowest uptake in the lung and kidney of the rats with CCl4-induced liver fibrosis.
Masahito Furukawa - One of the best experts on this subject based on the ideXlab platform.
-
Solvothermal preparation of potassium niobate/barium titanate Nanocomplex ceramics with three dimensional network-configuration of structure-gradient region and their dielectric properties
Journal of Applied Physics, 2013Co-Authors: Shintaro Ueno, Hideto Kawashima, Kouichi Nakashima, N Kumada, Eisuke Magome, Chikako Moriyoshi, Yoshihiro Kuroiwa, Yoshinori Fujikawa, Daiki Tanaka, Masahito FurukawaAbstract:To improve dielectric properties of barium titanate (BaTiO3, BT)-based ceramics, the BT/potassium niobate (KNbO3, KN) Nanocomplex ceramics were designed to expect the formation of a three dimensional network-configuration of a structure-gradient region (SGR), where the polar vector can easily rotate. The KN epitaxial nanolayers were formed on BT compacts with a necking structure by a solvothermal method and the maximal dielectric constant of 1450 and the relatively large apparent piezoelectric constant d33* of 318 pm/V were recorded for the KN/BT Nanocomplex ceramics. The experimental facts suggest that the configuration of the SGR, in addition to the relative density, is one of the important factors to enhance the dielectric properties of the KN/BT Nanocomplex ceramics.
-
solvothermal preparation of potassium niobate barium titanate Nanocomplex ceramics with three dimensional network configuration of structure gradient region and their dielectric properties
Journal of Applied Physics, 2013Co-Authors: Shintaro Ueno, Hideto Kawashima, Kouichi Nakashima, N Kumada, Eisuke Magome, Chikako Moriyoshi, Yoshihiro Kuroiwa, Yoshinori Fujikawa, Daisuke Tanaka, Masahito FurukawaAbstract:To improve dielectric properties of barium titanate (BaTiO3, BT)-based ceramics, the BT/potassium niobate (KNbO3, KN) Nanocomplex ceramics were designed to expect the formation of a three dimensional network-configuration of a structure-gradient region (SGR), where the polar vector can easily rotate. The KN epitaxial nanolayers were formed on BT compacts with a necking structure by a solvothermal method and the maximal dielectric constant of 1450 and the relatively large apparent piezoelectric constant d33* of 318 pm/V were recorded for the KN/BT Nanocomplex ceramics. The experimental facts suggest that the configuration of the SGR, in addition to the relative density, is one of the important factors to enhance the dielectric properties of the KN/BT Nanocomplex ceramics.
Ravi S. Shukla - One of the best experts on this subject based on the ideXlab platform.
-
Development of a Biocompatible Copolymer Nanocomplex to Deliver VEGF siRNA for Triple Negative Breast Cancer.
Theranostics, 2019Co-Authors: Zhen Zhao, Akshay Jain, Ashutosh Barve, Hao Liu, Ravi S. Shukla, Kun ChengAbstract:Triple negative breast cancer (TNBC) is the most difficult breast cancer subtype to treat. TNBC patients have significantly higher expression of vascular endothelial growth factor (VEGF) in tumors compared to non-TNBC patients. VEGF not only exerts its pro-angiogenic effects on endothelial cells but also acts as a survival and autocrine growth factor for VEGF receptor (VEGFR) expressing cancer cells. Silencing the expression of VEGF is therefore a potential therapy for TNBC. Methods: A novel biocompatible linear copolymer poly[bis(e-Lys-PEI)Glut-PEG] (PLEGP) was developed to deliver VEGF siRNA for TNBC therapy. The copolymer is composed of lysine and glutaric acid, a natural metabolite of amino acids in the body. Low-molecular weight polyethyleneimine (PEI) was grafted to the copolymer to efficiently condense siRNA into Nanocomplex without inducing cytotoxicity. Various in vitro studies were performed to evaluate the stability, cellular uptake, tumor penetration, and biological activities of the VEGF siRNA Nanocomplex. The anti-tumor activities of the Nanocomplex was also evaluated in an orthotopic TNBC mouse model. Results: PEIs with different molecular weights were evaluated, and the copolymer PLEGP1800 was able to easily form a stable Nanocomplex with siRNAs and protect them from serum degradation. The siRNA/PLEGP1800 Nanocomplex exhibited negligible cytotoxicity but showed high cellular uptake, high transfection efficiency, and high tumor penetration. In vitro activity studies showed that the siRNA Nanocomplex significantly inhibited migration and invasion of TNBC cells. Moreover, the VEGF siRNA Nanocomplex efficiently inhibited tumor growth in an orthotopic TNBC mouse model and down-regulated VEGF expression in the tumor. Conclusion: PLEGP1800 is a safe and efficient copolymer to deliver siRNAs for TNBC therapy. It could potentially be applied to other cancers by changing the cargo and incorporating tumor-specific ligands.
-
Intracellular trafficking and exocytosis of a multi-component siRNA Nanocomplex.
Nanomedicine : nanotechnology biology and medicine, 2016Co-Authors: Ravi S. Shukla, Akshay Jain, Zhen Zhao, Kun ChengAbstract:Despite the importance of siRNA delivery systems, understanding of their intracellular fate remains elusive. We recently developed a multi-component siRNA Nanocomplex to deliver siRNA to hepatic stellate cells (HSCs). The objective of this study is to study post-internalization trafficking of this siRNA Nanocomplex and its multiple components like siRNA, protamine, and streptavidin, in HSCs. After internalization, the Nanocomplex entrapped in early endosomes undergoes three possible routes including endosomal escape, exocytosis, and entrapment in lysosomes. Significant amount of siRNA dissociates from the Nanocomplex to exert silencing activity. After escaping from endosomes, protamine dissociates from the Nanocomplex and stays inside the cytoplasm. Golgi complex plays an important role in exocytosis of the Nanocomplex. We also demonstrate that exocytosis is one of the major reasons accounting for the transient silencing activity of nonviral siRNA delivery. Incorporation of exocytosis inhibitors in nonviral siRNA delivery systems may extend the silencing activity of siRNA.
-
Development of streptavidin-based Nanocomplex for siRNA delivery
Molecular pharmaceutics, 2013Co-Authors: Ravi S. Shukla, Wanyi Tai, Rubi Mahato, Wei Jin, Kun ChengAbstract:In our previous study, we have identified a PCBP2 siRNA that exhibits antifibrotic activity in rat hepatic stellate cells (HSCs) by inhibition of αCP2, a protein responsible for stabilization of the collagen α1 (I) mRNA in alcoholic liver fibrosis. This study aims to develop a streptavidin-based Nanocomplex that can efficiently deliver the PCBP2 siRNA to HSCs. Biotin–siRNA and biotin–cholesterol were mixed with streptavidin to form the streptavidin–biotin complex, which was further condensed electrostatically with positively charged protamine to form the final multicomponent siRNA Nanocomplex in the size range of 150–250 nm. The siRNA Nanocomplex does not induce cytotoxicity in rat HSCs as compared to commercially available transfection agents. The cellular uptake efficiency of the siRNA Nanocomplex is higher in rat HSCs than other cell lines, such as Caco-2 and PC-3, indicating that receptor-mediated endocytosis mainly contributes to the cellular uptake of the siRNA Nanocomplex. The siRNA Nanocomplex exh...
Zhen Zhao - One of the best experts on this subject based on the ideXlab platform.
-
Co-delivery of IKBKE siRNA and cabazitaxel by hybrid Nanocomplex inhibits invasiveness and growth of triple-negative breast cancer.
Science advances, 2020Co-Authors: Zhen Zhao, Akshay Jain, Hao Liu, Pratikkumar Patel, Kun ChengAbstract:IKBKE is an oncogene in triple-negative breast cancer (TNBC), and we demonstrate that IKBKE small interfering RNA (siRNA) inhibits the proliferation, migration, and invasion of TNBC cells. Despite the recent success of siRNA therapeutics targeting to the liver, there still remains a great challenge to deliver siRNAs to solid tumors. Here, we report a hybrid Nanocomplex to co-deliver the IKBKE siRNA and cabazitaxel to TNBC to achieve an optimal antitumor effect. The Nanocomplex is modified with hyaluronic acid to target CD44 on TNBC cells. The Nanocomplex shows higher cellular uptake and better tumor penetration of the encapsulated cargos. The Nanocomplex also exhibits high tumor accumulation and antitumor activity in an orthotopic TNBC mouse model. Encapsulation of cabazitaxel in the Nanocomplex enhances the activity of the IKBKE siRNA. The hybrid Nanocomplex provides a novel and versatile platform for combination therapies using siRNAs and chemotherapy.
-
Abstract 351: A targeted Nanocomplex of the IKBKE siRNA inhibits invasiveness and growth of triple negative breast cancer cells
Experimental and Molecular Therapeutics, 2019Co-Authors: Zhen Zhao, Kun ChengAbstract:IκB kinase e (IKBKE, or known as IKKe), an important mediator in the activation of NF-κB pathway, was recently identified as an oncogene in breast cancer and overexpressed in approximately 30% of breast carcinomas. It is also highly expressed in TNBC cells, which is correlated with angiogenesis process, high metastasis in NF-κB pathway of TNBC. We found that silencing IKBKE in TNBC cells using siRNA significantly inhibits the proliferation, migration and invasion of TNBC cells by specific silenced 71% of IKBKE in vitro. In vivo study indicated that IKBKE siRNA can inhibit TNBC tumor growth after peritumoral injection at a IKBKE siRNA dose of 0.3 mg/kg. We next developed a CD44-targeting, cholesterol-peptide based Nanocomplex to co-deliver the IKBKE siRNA and cabazitaxel to TNBC cells. The Nanocomplex showed the synergistic effect of the IKBKE siRNA and cabazitaxel on inhibiting the growth of TNBC tumors in vivo. Modification of the Nanocomplex with CD44 further improved tumor uptake and anti-tumor efficacy of the Nanocomplex. Our results suggest that IKBKE siRNA is a promising anti-tumor agent for TNBC therapy, and co-delivery of IKBKE siRNA and cabazitaxel using a CD44-targeting Nanocomplex is a potential strategy for TNBC treatment. Moreover, this multifunctional delivery system provides a platform for other combination therapy including an siRNA and a chemotherapy drug. Citation Format: Zhen Zhao, Yuanke Li, Kun Cheng. A targeted Nanocomplex of the IKBKE siRNA inhibits invasiveness and growth of triple negative breast cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 351.
-
Targeted Delivery of an siRNA/PNA Hybrid Nanocomplex Reverses Carbon Tetrachloride-Induced Liver Fibrosis.
Advanced therapeutics, 2019Co-Authors: Akshay Jain, Ashutosh Barve, Zhen Zhao, John Peter Fetse, Hao Liu, Kun ChengAbstract:Liver fibrosis is a wound healing process with excessive accumulation of extracellular matrix in the liver. We recently discovered a PCBP2 siRNA that reverses fibrogenesis in activated hepatic stellate cells (HSCs), which are the key players in liver fibrogenesis. However, targeted delivery of siRNAs to HSCs still remains a challenge. Herein, we developed a new strategy to fabricate a multicomponent Nanocomplex using siRNA/PNA hybrid instead of chemically conjugated siRNA, thus increasing the scalability and feasibility of the siRNA Nanocomplex for animal studies. We modified the Nanocomplex with an insulin growth factor 2 receptor (IGF2R)-specific peptide, which specifically binds to activated HSCs. The siRNA Nanocomplex shows a controllable size and high serum stability. The Nanocomplex also demonstrates high cellular uptake in activated HSCs in vitro and in vivo. Anti-fibrotic activity of the siRNA Nanocomplex was evaluated in rats with carbon tetrachloride-induced liver fibrosis. Treatment with the PCBP2 siRNA Nanocomplex significantly inhibits the mRNA expressions of PCBP2 and type I collagen in fibrotic liver. Histology study revealed that the siRNA Nanocomplex efficiently reduces the protein level of type I collagen and reverses liver fibrosis. Our data suggest that the Nanocomplex efficiently delivers the siRNA to fibrotic liver and produces a potent anti-fibrotic effect.
-
Development of a Biocompatible Copolymer Nanocomplex to Deliver VEGF siRNA for Triple Negative Breast Cancer.
Theranostics, 2019Co-Authors: Zhen Zhao, Akshay Jain, Ashutosh Barve, Hao Liu, Ravi S. Shukla, Kun ChengAbstract:Triple negative breast cancer (TNBC) is the most difficult breast cancer subtype to treat. TNBC patients have significantly higher expression of vascular endothelial growth factor (VEGF) in tumors compared to non-TNBC patients. VEGF not only exerts its pro-angiogenic effects on endothelial cells but also acts as a survival and autocrine growth factor for VEGF receptor (VEGFR) expressing cancer cells. Silencing the expression of VEGF is therefore a potential therapy for TNBC. Methods: A novel biocompatible linear copolymer poly[bis(e-Lys-PEI)Glut-PEG] (PLEGP) was developed to deliver VEGF siRNA for TNBC therapy. The copolymer is composed of lysine and glutaric acid, a natural metabolite of amino acids in the body. Low-molecular weight polyethyleneimine (PEI) was grafted to the copolymer to efficiently condense siRNA into Nanocomplex without inducing cytotoxicity. Various in vitro studies were performed to evaluate the stability, cellular uptake, tumor penetration, and biological activities of the VEGF siRNA Nanocomplex. The anti-tumor activities of the Nanocomplex was also evaluated in an orthotopic TNBC mouse model. Results: PEIs with different molecular weights were evaluated, and the copolymer PLEGP1800 was able to easily form a stable Nanocomplex with siRNAs and protect them from serum degradation. The siRNA/PLEGP1800 Nanocomplex exhibited negligible cytotoxicity but showed high cellular uptake, high transfection efficiency, and high tumor penetration. In vitro activity studies showed that the siRNA Nanocomplex significantly inhibited migration and invasion of TNBC cells. Moreover, the VEGF siRNA Nanocomplex efficiently inhibited tumor growth in an orthotopic TNBC mouse model and down-regulated VEGF expression in the tumor. Conclusion: PLEGP1800 is a safe and efficient copolymer to deliver siRNAs for TNBC therapy. It could potentially be applied to other cancers by changing the cargo and incorporating tumor-specific ligands.
-
Development of a peptide-modified siRNA Nanocomplex for hepatic stellate cells.
Nanomedicine : nanotechnology biology and medicine, 2017Co-Authors: Zhen Zhao, Akshay Jain, Hao Liu, Wei Jin, Zhijin Chen, Kun ChengAbstract:Insulin-like growth factor 2 receptor (IGF2R) is overexpressed in activated hepatic stellate cells (HSCs) and therefore can be utilized for HSC-specific drug delivery. We recently discovered an IGF2R-specific peptide using a novel biopanning. Here, we adopted biotin-conjugated IGF2R-specific peptide, cholesterol, and vitamin A as the targeting ligands for the neutravidin-based siRNA Nanocomplex to deliver PCBP2 siRNA, a potentially antifibrotic agent, to HSCs. Compared to vitamin A and cholesterol, the IGF2R-specific peptide exhibited the highest targeting effect to human LX-2 HSC, rat HSC-T6 cell line, and activated primary rat HSCs. Accordingly, the IGF2R-specific peptide coupled Nanocomplex demonstrated higher silencing activity of PCBP2 and better inhibition on the migration of activated HSCs. Compared to free siRNA and the Nanocomplexes coupled with vitamin A and cholesterol, the IGF2R-specific peptide coupled Nanocomplex showed the highest uptake in the liver and lowest uptake in the lung and kidney of the rats with CCl4-induced liver fibrosis.
Xiaohong Zhang - One of the best experts on this subject based on the ideXlab platform.
-
a reticuloendothelial system stealthy dye albumin Nanocomplex as a highly biocompatible and highly luminescent nanoprobe for targeted in vivo tumor imaging
RSC Advances, 2014Co-Authors: Yinlong Yang, Juan Liu, Jinfeng Zhang, Mengjiao Zhou, Xiujuan Zhang, Cai-jun Zheng, Xing-jie Liang, Xiaohong ZhangAbstract:A reticuloendothelial system (RES)-stealthy nanoprobe for enhanced tumor imaging is a longstanding pursuit. In this study, a Nanocomplex comprising albumin and dye is assembled without crosslinker use. The Nanocomplex shows intense luminescence with a photoluminescence quantum yield of up to 0.39 and a large Stokes shift of >130 nm. The Nanocomplex also exhibits higher stability against hydrolysis than indocyanine green during the 14 days test. The Nanocomplex shows favourable high biocompatibility and can be used for cell labelling. Remarkably, the Nanocomplex exhibits six times higher tumor accumulation than that in the liver and spleen. At 96 h post-injection, the nanoprobe is still observable and gives a clear imaging of tumors, which can help in convenient diagnosis post-injection.
-
A reticuloendothelial system-stealthy dye–albumin Nanocomplex as a highly biocompatible and highly luminescent nanoprobe for targeted in vivo tumor imaging
RSC Advances, 2014Co-Authors: Yinlong Yang, Juan Liu, Jinfeng Zhang, Mengjiao Zhou, Xiujuan Zhang, Cai-jun Zheng, Xing-jie Liang, Xiaohong ZhangAbstract:A reticuloendothelial system (RES)-stealthy nanoprobe for enhanced tumor imaging is a longstanding pursuit. In this study, a Nanocomplex comprising albumin and dye is assembled without crosslinker use. The Nanocomplex shows intense luminescence with a photoluminescence quantum yield of up to 0.39 and a large Stokes shift of >130 nm. The Nanocomplex also exhibits higher stability against hydrolysis than indocyanine green during the 14 days test. The Nanocomplex shows favourable high biocompatibility and can be used for cell labelling. Remarkably, the Nanocomplex exhibits six times higher tumor accumulation than that in the liver and spleen. At 96 h post-injection, the nanoprobe is still observable and gives a clear imaging of tumors, which can help in convenient diagnosis post-injection.
